Roche 1Q13 1Q Revenues: $12.5 billion (+4%) 1Q Earnings: not disclosed Comments: Pharma revenues overall rose 5% to $9.9 billion, with U.S. sales up 13% to $4.2 billion, European sales up 1% to $2.5 billion, Japanese sales down 12% to $888 million, and rest-of-world sales up 6% to $2.3 billion. Rituxan sales were up 6% to $1.8 billion; Herceptin sales rose 11% to $1.7 billion and Avastin sales climbed 11% to $1.6 billion. Tamiflu sales were up 84% to $360 million in the quarter, and Actemra c...